Questions for 5 April Investor Call, page-101

Attachment 1 Appendix 4D
Interim Consolidated Financial Report for the period ended 31 December 2014

 5,000,000 performance rights to vest upon receipt by the Company of the first royalty payment
resulting from a licence to a third party of the Company’s powered Dermaportation technology
(Milestone 1);
 5,000,000 performance rights to vest upon the execution of a new licence agreement with a
third party for the utilisation of the Company’s ETP technology (Milestone 2); and
 5,000,000 performance rights to vest upon the receipt by the Company of licensing fees in
excess of $20,000,000 (Milestone 3).

Qu: With regards to the Milestone 3 target. How exactly was this milestone conceived & then calculated?

Yes this now ancient history and yes we should all move on, but surely as a share holder do you not want this cleared up. $20,000,000 was a huge target set in late 2014 and provided some expectation that this target may be reflective of what OBJ knew at the time in relation to the licensing fees that it negotiated with partners.
Surely this calculation isn't still embargoed due to confidentiality.
Transparency is what I require, since this will clear some of the air and possibly put to bed what most of us are thinking about this board but aren't allowed to post publicly.